PURPOSE: The primary objective of Children's Oncology Group study P9641 was to demonstrate that surgery alone would achieve 3-year overall survival (OS) ≥ 95% for patients with asymptomatic International Neuroblastoma Staging System stages 2a and 2b neuroblastoma (NBL). Secondary objectives focused on other low-risk patients with NBL and on those who required chemotherapy according to protocol-defined criteria. PATIENTS AND METHODS: Patients underwent maximally safe resection of tumor. Chemotherapy was reserved for patients with, or at risk for, symptomatic disease, with less than 50% tumor resection at diagnosis, or with unresectable progressive disease after surgery alone. RESULTS: For all 915 eligible patients, 5-year event-free survival (EFS) and OS were 89% ± 1% and 97% ± 1%, respectively. For patients with asymptomatic stage 2a or 2b disease, 5-year EFS and OS were 87% ± 2% and 96% ± 1%, respectively. Among patients with stage 2b disease, EFS and OS were significantly lower for those with unfavorable histology or diploid tumors, and OS was significantly lower for those ≥ 18 months old. For patients with stage 1 and 4s NBL, 5-year OS rates were 99% ± 1% and 91% ± 1%, respectively. Patients who required chemotherapy at diagnosis achieved 5-year OS of 98% ± 1%. Of all patients observed after surgery, 11.1% experienced recurrence or progression of disease. CONCLUSION: Excellent survival rates can be achieved in asymptomatic low-risk patients with stages 2a and 2b NBL after surgery alone. Immediate use of chemotherapy may be restricted to a minority of patients with low-risk NBL. Patients with stage 2b disease who are older or have diploid or unfavorable histology tumors fare less well. Future studies will seek to refine risk classification.
PURPOSE: The primary objective of Children's Oncology Group study P9641 was to demonstrate that surgery alone would achieve 3-year overall survival (OS) ≥ 95% for patients with asymptomatic International Neuroblastoma Staging System stages 2a and 2b neuroblastoma (NBL). Secondary objectives focused on other low-risk patients with NBL and on those who required chemotherapy according to protocol-defined criteria. PATIENTS AND METHODS: Patients underwent maximally safe resection of tumor. Chemotherapy was reserved for patients with, or at risk for, symptomatic disease, with less than 50% tumor resection at diagnosis, or with unresectable progressive disease after surgery alone. RESULTS: For all 915 eligible patients, 5-year event-free survival (EFS) and OS were 89% ± 1% and 97% ± 1%, respectively. For patients with asymptomatic stage 2a or 2b disease, 5-year EFS and OS were 87% ± 2% and 96% ± 1%, respectively. Among patients with stage 2b disease, EFS and OS were significantly lower for those with unfavorable histology or diploid tumors, and OS was significantly lower for those ≥ 18 months old. For patients with stage 1 and 4s NBL, 5-year OS rates were 99% ± 1% and 91% ± 1%, respectively. Patients who required chemotherapy at diagnosis achieved 5-year OS of 98% ± 1%. Of all patients observed after surgery, 11.1% experienced recurrence or progression of disease. CONCLUSION: Excellent survival rates can be achieved in asymptomatic low-risk patients with stages 2a and 2b NBL after surgery alone. Immediate use of chemotherapy may be restricted to a minority of patients with low-risk NBL. Patients with stage 2b disease who are older or have diploid or unfavorable histology tumors fare less well. Future studies will seek to refine risk classification.
Authors: Jo Vandesompele; Michael Baudis; Katleen De Preter; Nadine Van Roy; Peter Ambros; Nick Bown; Christian Brinkschmidt; Holger Christiansen; Valérie Combaret; Maria Lastowska; James Nicholson; Anne O'Meara; Dominique Plantaz; Raymond Stallings; Bénédicte Brichard; Caroline Van den Broecke; Sylvia De Bie; Anne De Paepe; Geneviève Laureys; Frank Speleman Journal: J Clin Oncol Date: 2005-04-01 Impact factor: 44.544
Authors: R P Castleberry; J J Shuster; G Altshuler; E I Smith; R Nitschke; N Winick; N McWilliams; V Joshi; F A Hayes Journal: J Clin Oncol Date: 1992-08 Impact factor: 44.544
Authors: L C Bowman; R P Castleberry; A Cantor; V Joshi; S L Cohn; E I Smith; A Yu; G M Brodeur; F A Hayes; A T Look Journal: J Natl Cancer Inst Date: 1997-03-05 Impact factor: 13.506
Authors: D N Shapiro; M B Valentine; S T Rowe; A E Sinclair; J E Sublett; W M Roberts; A T Look Journal: Am J Pathol Date: 1993-05 Impact factor: 4.307
Authors: G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg Journal: J Clin Oncol Date: 1993-08 Impact factor: 44.544
Authors: H Shimada; J Chatten; W A Newton; N Sachs; A B Hamoudi; T Chiba; H B Marsden; K Misugi Journal: J Natl Cancer Inst Date: 1984-08 Impact factor: 13.506
Authors: D Strother; J J Shuster; N McWilliams; R Nitschke; E I Smith; V J Joshi; L Kun; F A Hayes; R Castleberry Journal: J Pediatr Hematol Oncol Date: 1995-08 Impact factor: 1.289
Authors: Navin Pinto; Jodi R Mayfield; Gordana Raca; Mark A Applebaum; Alexandre Chlenski; Madina Sukhanova; Rochelle Bagatell; Meredith S Irwin; Anthony Little; Jawhar Rawwas; Yasmin Gosiengfiao; Olivier Delattre; Isabelle Janoueix-Lerosey; Eve Lapouble; Gudrun Schleiermacher; Susan L Cohn Journal: Pediatr Blood Cancer Date: 2016-02-10 Impact factor: 3.167
Authors: Maya Suzuki; Brian H Kushner; Kim Kramer; Ellen M Basu; Stephen S Roberts; William J Hammond; Michael P LaQuaglia; Suzanne L Wolden; Nai-Kong V Cheung; Shakeel Modak Journal: Int J Cancer Date: 2018-04-06 Impact factor: 7.396
Authors: Kelly E Huibregtse; Kieuhoa T Vo; Steven G DuBois; Stephanie Fetzko; John Neuhaus; Vandana Batra; John M Maris; Brian Weiss; Araz Marachelian; Greg A Yanik; Katherine K Matthay Journal: Eur J Cancer Date: 2016-08-27 Impact factor: 9.162